Which Patients Report That Their Urologists Advised Them to Forgo Initial Treatment for Prostate Cancer?

被引:3
|
作者
Radhakrishnan, Archana
Grande, David
Mitra, Nandita
Pollack, Craig Evan
机构
[1] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA
[3] Johns Hopkins Univ, Div Gen Internal Med, Baltimore, MD USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
关键词
ACTIVE SURVEILLANCE; DECISION-MAKING; OLDER-ADULTS; MEN CHOOSE; PROGNOSIS; RISK; MANAGEMENT; PHYSICIANS; CARE;
D O I
10.1016/j.urology.2018.01.048
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To examine how frequently patients report that their urologist recommended forgoing definitive treatment and assess the impact of these recommendations on treatment choice and perceived quality of cancer care. METHODS We mailed surveys to men newly diagnosed with localized prostate cancer between 2014 and 2015 (adjusted response rate of 51.3%). Men reported whether their urologist recommended forgoing definitive treatment. Using logistic regression models, we assessed patient-level predictors of receiving a recommendation to forgo definitive treatment and estimated associations of receiving this recommendation with receipt of definitive treatment and perceived quality of cancer care among men with low-risk tumors and limited life expectancies. RESULTS Nearly two-thirds (62.2%) of men with low-risk tumors and 46.4% with limited life expectancies received recommendations from their urologists to forgo definitive treatment. Among men with limited life expectancies, those with low-risk tumors were more likely to receive this recommendation compared with men with high-risk tumors (odds ratio [OR] 3.41; 95% confidence interval [CI] 2.17-5.37). Men with low-risk tumors who were recommended to forgo definitive treatment were less likely to receive definitive treatment (OR 0.48; 95% CI 0.32-0.73) but did not report lower perceived quality of care (OR 0.97; 95% CI 0.63-1.48). CONCLUSION In this population-based study, a majority of men with low-risk prostate cancer report receiving recommendations from their urologists to forgo definitive treatment. Our results suggest that urologists have a strong influence on patient treatment choice and could increase active surveillance uptake in men eligible for expectant management without patients perceiving lower quality of cancer care. (C) 2018 Elsevier Inc.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 50 条
  • [21] Observation Versus Initial Treatment for Prostate Cancer
    Pinsky, Paul
    ANNALS OF INTERNAL MEDICINE, 2013, 159 (08) : 574 - 574
  • [22] Referral patterns and treatment preferences in patients with advanced prostate cancer (aPC): Differences between medical oncologists and urologists
    Gajra, Ajeet
    Hime, Skyler
    Jeune-Smith, Yolaine
    Russell, Amy
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [23] A Success Story for Patients and Urologists: Publishing the evaluation of the Prostate Cancer Decision Aid
    Merseburger, Axel
    UROLOGIE, 2024, 63 (05): : 508 - 509
  • [24] Pancytopenia as an initial manifestation of prostate cancer: a case report
    Marcos Antonio Custódio Neto da Silva
    Vitor Pimentel Rodrigues Manhães
    Luadir Gasparotto Júnior
    Daniela Miti Lemos Tsukumo
    Cristina Alba Lalli
    Journal of Medical Case Reports, 15
  • [25] Pancytopenia as an initial manifestation of prostate cancer: a case report
    Custodio Neto da Silva, Marcos Antonio
    Rodrigues Manhaes, Vitor Pimentel
    Gasparotto Junior, Luadir
    Lemos Tsukumo, Daniela Miti
    Lalli, Cristina Alba
    JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
  • [26] Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapists
    Gravina, Giovanni L.
    Di Sante, Stefania
    Limoncin, Erika
    Mollaioli, Daniele
    Ciocca, Giacomo
    Carosa, Eleonora
    Sanita, Patrizia
    Di Cesare, Ernesto
    Lenzi, Andrea
    Jannini, Emmanuele A.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (02) : 139 - 147
  • [27] Which results justify the means in prostate cancer treatment?
    Albertsen, PC
    CANCER JOURNAL, 2002, 8 (01): : 30 - 32
  • [28] Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?
    Milecki, Tomasz
    Antczak, Andrzej
    Kwias, Zbigniew
    Milecki, Piotr
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2015, 19 (01): : 1 - 5
  • [29] QUALITY OF TREATMENT WITH TARGETED THERAPIES FOR ADVANCED PROSTATE CANCER BY SPECIALIST: DO PATIENTS WHO ARE MANAGED BY UROLOGISTS FARE DIFFERENTLY?
    Faraj, Kassem
    Oerline, Mary
    Kaufman, Samuel
    Maganty, Avinash
    Caram, Megan
    Shahinian, Vahakn
    Hollenbeck, Brent
    JOURNAL OF UROLOGY, 2024, 211 (05): : E66 - E66
  • [30] TREATMENT PREFERENCES OF UROLOGISTS IN GREAT-BRITAIN AND IRELAND IN THE MANAGEMENT OF PROSTATE-CANCER
    WAYMONT, B
    LYNCH, TH
    DUNN, J
    BATHERS, S
    WALLACE, DMA
    BRITISH JOURNAL OF UROLOGY, 1993, 71 (05): : 577 - 582